Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BE-106 is an investigational microbiome-derived biotic (MDB) developed by BiomEdit for animal health applications. It is part of BiomEdit's "Investigational Projects" pipeline, which focuses on utilizing bacterial consortia or engineered bacterial vectors to address specific health and performance challenges in livestock. The product is designed to modulate the gastrointestinal microbiome to provide therapeutic benefits, such as pathogen protection or improved feed efficiency, while reducing reliance on traditional antibiotics. BE-106 is currently in the candidate optimization to proof-of-concept stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BE-106.